Disney’s latest remake, “Snow White,” arrived in theaters on Thursday night as one of the most snakebit projects in the company’s 102-year history. Almost everything that could go wrong did, resulting in a torrent of negative prerelease publicity.

Did the tumult have an impact on the box office?

It certainly didn’t help: Based on projections from analysts, “Snow White” will finish the weekend with a saggy $45 million in ticket sales. In the 15 years that Disney has been producing live-action remakes of its animated classics, none of the big-budget entries have arrived in theaters to less than $58 million, after adjusting for inflation. (That was “Dumbo” in 2019.)

“Snow White” collected an additional $44 million or so overseas this weekend, according to Disney. The movie cost at least $350 million to make and market (on par with “Dumbo” after adjusting for inflation).

Despite its slow start, “Snow White” was the No. 1 movie in the United States and Canada over the weekend, according to Comscore, which compiles box office data. It played in 4,200 theaters and gave the struggling movie theater business its second-biggest opening of the year, behind Disney’s “Captain America: Brave New World,” which had $89 million in first-weekend ticket sales.

Among other new releases, the gangster drama “The Alto Knights” (Warner Bros.), which cost roughly $50 million to make,66br excluding marketing, collected a disastrous $3 million from 2,651 theaters. It received weak reviews.

“Magazine Dreams” (Briarcliff), a gritty bodybuilder drama starring Jonathan Majors, took in about $700,000 from 815 theaters, a result that The Hollywood Reporter called “D.O.A.” Mr. Majors had promoted the film as a comeback vehicle after his career took a hit when he was convicted in 2023 of assaulting and harassing an ex-girlfriend. Reviews were mostly positive.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

This was no rescue: Mr. Siffre, a geologist, was conducting an experiment on himself, to see what would happen to his sense of time if he cut himself off from the normal day-night flow of life on the surface.

AstraZeneca, which makes the treatment, said it would start a FluMist Home website, where people can fill out a questionnaire that will be reviewed by a pharmacist before the treatment is shipped to a person’s home. The mist will remain available from prescribers as an in-office treatment. The current out-of-pocket cost for a dose is about $35 to $45, but may be less depending on insurance coverage.

jqkbet

Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.funkpg